Institutional shares held 13.4 Million
44.9K calls
8.1K puts
Total value of holdings $19M
$63K calls
$11K puts
Market Cap $123M
86,624,600 Shares Out.
Institutional ownership 15.45%
# of Institutions 77


Latest Institutional Activity in CGEN

Top Purchases

Q1 2025
Calamos Wealth Management LLC Shares Held: 29.5K ($41.9K)
Q1 2025
Janney Montgomery Scott LLC Shares Held: 29.2K ($41.5K)
Q1 2025
Eagle Rock Investment Company, LLC Shares Held: 71.2K ($101K)
Q1 2025
Oppenheimer & CO Inc Shares Held: 56.6K ($80.4K)
Q4 2024
Northern Trust Corp Shares Held: 942K ($1.34M)

Top Sells

Q1 2025
Taylor Frigon Capital Management LLC Shares Held: 1.05M ($1.49M)
Q1 2025
Rothschild Investment LLC Shares Held: 191K ($272K)
Q1 2025
Joel Isaacson & Co., LLC Shares Held: 12K ($17K)
Q1 2025
Ewa, LLC Shares Held: 65.2K ($92.6K)
Q4 2024
Jpmorgan Chase & CO Shares Held: 12.1K ($17.2K)

About CGEN

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.


Insider Transactions at CGEN

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
0 Shares
From 0 Insiders
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on CGEN

Follow COMPUGEN LTD and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CGEN shares.

Notify only if
Any

Insider Trading

Get notified when an Compugen LTD insider buys or sells CGEN shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to COMPUGEN LTD

Track Activities on CGEN